Find An Allergist / Immunologist | Pollen Counts | Journal of Allergy and Clinical Immunology | Annual Meeting   Site Map   Contact   Home    Search
Meeting Home Preliminary Program Abstracts • Poster Preparation Guidelines • Awards • View 2004 Abstracts Speakers Industry/Exhibitors Frequently Asked Questions About San Antonio Contact Us AAAAI Home		Late Breaking Abstract Preparation Guidelines The late breaking abstract submission site has closed. These guidelines are for reference only. 1. Organization of Abstract Body. Organize the body of abstract as follows: (1) Rationale. A statement of purpose of the study (preferably one sentence). (2) Methods. A brief statement of the methods used. For abstracts reporting clinical research, a sentence or phrase presenting the most important selection criteria for subjects should be included. (3) Results. A summary of the results presented in sufficient detail with statistical analysis to support the conclusions. (4) Conclusions. A statement of the conclusions reached. It is not satisfactory to state, "the results will be discussed," or "other data will be presented," etc. Be sure to use the words Rationale, Methods, Results and Conclusions in the body of your abstract to indicate the start of each new section. See the Sample Late Breaking Abstract for an example. 2. Abstract Length. The maximum length of a late breaking abstract submitted for presentation at the 2005 Annual Meeting is 254 words. The title and author information are not included in this limitation. Tables and graphs are not permitted. 3. Title. Capitalize only the first letter of each word of the title. Bold the title and do not place a period on the end. 4. Abbreviations. The use of standard abbreviations is desirable (i.e., rbc, kg, mg). A special or unusual abbreviation should be placed in parentheses after the first appearance of the full word for which it represents. Do not use periods after abbreviations or initials. Numerals rather than words should indicate numbers, except to begin sentences. 5. Drug Names. Each time a proprietary drug name is used in the abstract, the first letter is capitalized. Non proprietary (generic) names are preferred and are not capitalized. 6. Format. You may use your word processor's capabilities for bold, underline, italic, subscript and superscript, or use the tools provided when entering your abstract. Bold the words Rationale, Methods, Results and Conclusions used to separate one section of the abstract from another. Text that will be italic in published form (e.g., genus, species) may be formatted as italics. 7. Revisions. You may come back to the site and edit your late breaking abstract until the December 13, 2004 deadline. After December 13, 2004, no revisions will be accepted. Abstracts will appear in the supplement exactly as submitted. No extensions or revisions will be allowed for submission, including author changes. Sample Late Breaking Abstract Cytokines Enhance Epithelial Cell (EC) Damage Caused by Rhinovirus D.M. Galagan, M.K. Schroth, E.D. Dick, W.W. Busse, J.E. Gern UW Hospital and Clinics, Madison, WI RATIONALE: Since the major group rhinovirus (RV) receptor, ICAM-1, is inducible with cytokines such as TNF that may be present in the allergic airway, we examined the separate and combined effects of RV and TNF on EC viability in vitro. METHODS: EC isolated from nasal polyp tissue were incubated with either serum free medium or TNF(10 U/ml). After 24 hours, EC were inoculated with RV49, a minor group RV which binds to the low density lipoprotein receptor, RV16. RESULTS: Pre-incubating cells with TNF before RV inoculation produced additive epithelial cell damage compared to RV inoculation alone (n=3 experiments) (p=0.05). CONCLUSIONS: Thus patients with pre-existing airway allergic inflammation may develop increased epithelial cell damage following RV infection. Abstract Policies and Procedures 1. Submission Deadline. Late breaking abstracts must be received by December 13, 2004. 2. Previous Presentations of Abstracts. No late breaking abstracts previously published as an article or presented at the national meetings of other organizations prior to the time of the 2005 Annual Meeting may be presented. If a person knowingly submits a late breaking abstract published as an article or presented at another national meeting, that person may not submit an abstract for the next two Annual Meetings. 3. Abstract Submitters. Late breaking abstracts may be submitted by fellows, members and non members of the AAAAI. An individual may be the presenting author of only one late breaking abstract at the 2005 Annual Meeting. Sponsorship or co-authorship of additional abstracts is permitted. 4. Abstract Presenters. If accepted for presentation, the first author is the individual who must present the late breaking abstract in an oral session. An individual may present only one late breaking abstract at the 2005 Annual Meeting. Those individuals listed as first authors on regular abstracts are NOT prohibited from submitting a late breaking abstract. A speaker who is invited to present a regular abstract or speak at a postgraduate session, symposium, workshop or seminar does not lose the privilege of presenting a late breaking abstract, provided that each presentation is substantially and recognizably different from the other in concept and data. 5. Duplicate Abstracts. In an effort to reduce the amount of duplicate abstracts submitted, only one late breaking abstract per clinical study will be allowed from any one laboratory, institution, or group of investigators. Abstracts summarizing significantly different aspects and presenting significantly different conclusions using the same study population will be allowed, but multiple abstracts focusing on the same or slightly different aspects of the same study are prohibited. 6. Tracks and Keywords. Each late breaking abstract must be submitted within one track and with up to three keywords, chosen by the first and submitting author. This information will be used to assist in the systematic review and organization of late breaking abstracts and their subsequent presentations. Abstract submitters should provide the appropriate notations on the online submission form. Late breaking abstracts submitted without this information will not be reviewed for presentation at the 2005 Annual Meeting. 7. Funding. The source of funding of the research summarized in the late breaking abstract must be disclosed at the time of submission. Abstract submitters must provide this information in the appropriate section of the online submission form. 8. Conflicts of Interest. Late breaking abstract presenters must disclose to participants any conflicts of interest they might have with the contents of their abstracts and presentations. A conflict of interest includes, but is not limited to, any significant financial interest in a company, product or procedure that is mentioned in an abstract or presentation to be given at the meeting, or any significant financial interest in the organization providing funding for the research summarized in the abstract. The AAAAI will collect this information from all abstract submitters at the time of submission. If the first and submitting author feels that such a conflict of interest exists, the conflict should be noted on the online submission form so the AAAAI may communicate that information to the participants. A conflict of interest will not affect whether a late breaking abstract is accepted for presentation at the 2005 Annual Meeting. 9. Informed Consent. Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966; 14:103) and must meet all the requirements governing informed consent of the country in which the research was performed. Abstract submitters must confirm that such procedures were followed at the time of submission by making the appropriate affirmation on the online submission form. Submitters who do not provide the appropriate notation will not be allowed to submit an abstract for the 2005 Annual Meeting. 10. Use of Animals. All studies involving the use of animals must conform with the 1991 revision of "Guiding Principles in the Care and Use of Animals" (American Physiological Association, Bethesda, MD 20814 3991). 11. Abstract Supplement. All late breaking abstracts presented at the 2005 Annual Meeting will be published in a later edition of the AAAAI's official journal, The Journal of Allergy and Clinical Immunology, and become the property of the journal publisher. Ownership of submitted abstracts not accepted for presentation reverts to the author. 12. Submission Fee. Each late breaking abstract submission must be accompanied by a $50 processing fee. Payment must be made by credit card. Complete the credit card information on the online submission form. Abstracts received without payment will not be reviewed for presentation at the 2005 Annual Meeting. The fee is not refundable, even if the abstract is not accepted. 13. Notification of Programming. If the late breaking abstract is accepted for presentation at the 2005 Annual Meeting, the first and submitting author will be notified by January 21, 2005. Late Breaking Abstract Tracks The AAAAI will consider late breaking abstracts in the following tracks for presentation at the 2005 Annual Meeting. Abstract submitters will be asked to select the one track from below that best describes their abstract on the online submission form. CLINICAL abstracts are those that deal predominantly with topics related to in vivo studies of human patients (minimal animal studies or bench research). TRANSLATIONAL abstracts are those that present a "bench to bedside" approach, combining both clinical and basic topics in approximately equal amounts. BASIC abstracts deal predominately with topics related to bench research such as in vitro studies of cells, tissues, genes, signaling pathways, allergens, etc., OR with topics in in vivo animal models of disease (minimal human in vivo studies). <back>
	© 1996-2009 · All Rights Reserved · American Academy of Allergy Asthma & Immunology